FDA advisers are voting on Grail's multicancer blood test as Medicare coverage hangs in the balance
发生了什么
The Molecular and Clinical Genetics Panel is weighing the Galleri test's clinical evidence today; Medicare coverage could follow FDA approval
摘要按规则整理自下方来源原文